{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:26:00Z","timestamp":1779877560179,"version":"3.53.1"},"reference-count":121,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":1005,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["TS150032 W21XWH-16\u20131-0187"],"award-info":[{"award-number":["TS150032 W21XWH-16\u20131-0187"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007928","name":"Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","award":["MDBR-17\u2013118-LAM"],"award-info":[{"award-number":["MDBR-17\u2013118-LAM"]}],"id":[{"id":"10.13039\/100007928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["17\u201315-01368"],"award-info":[{"award-number":["17\u201315-01368"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL116916"],"award-info":[{"award-number":["HL116916"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL114085"],"award-info":[{"award-number":["HL114085"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL131626"],"award-info":[{"award-number":["HL131626"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1074\/jbc.m117.799593","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T00:25:18Z","timestamp":1506990318000},"page":"20528-20543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors"],"prefix":"10.1016","volume":"292","author":[{"given":"Victoria","family":"Stepanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin V.","family":"Dergilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelci R.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena V.","family":"Parfyonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya I.","family":"Tsokolaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Teter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena N.","family":"Atochina-Vasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Volgina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei V.","family":"Zaitsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane P.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedor G.","family":"Zabozlaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kseniya","family":"Obraztsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera P.","family":"Krymskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Cines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.M117.799593_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-med-050715-104245","article-title":"Lymphangioleiomyomatosis: a monogenic model of malignancy","volume":"68","author":"Krymskaya","year":"2017","journal-title":"Annu. Rev. Med"},{"key":"10.1074\/jbc.M117.799593_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/35101031","article-title":"Two genetic hits (more or less) to cancer","volume":"1","author":"Knudson","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1074\/jbc.M117.799593_bib3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.celrep.2014.06.064","article-title":"Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638\/Dnm2 as a two-hit oncogenic locus","volume":"8","author":"Tay","year":"2014","journal-title":"Cell Rep"},{"key":"10.1074\/jbc.M117.799593_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2217\/fon.12.26","article-title":"Inactivation of X-linked tumor suppressor genes in human cancer","volume":"8","author":"Liu","year":"2012","journal-title":"Future Oncol"},{"key":"10.1074\/jbc.M117.799593_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1378\/chest.07-0898","article-title":"Lymphangioleiomyomatosis: a clinical update","volume":"133","author":"McCormack","year":"2008","journal-title":"Chest"},{"key":"10.1074\/jbc.M117.799593_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1086\/301804","article-title":"Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis","volume":"62","author":"Smolarek","year":"1998","journal-title":"Am. J. Hum. Genet"},{"key":"10.1074\/jbc.M117.799593_bib7","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","article-title":"Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc","volume":"97","author":"Carsillo","year":"2000","journal-title":"Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.M117.799593_bib8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1165\/rcmb.2006-0372TR","article-title":"Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans","volume":"36","author":"Juvet","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol"},{"key":"10.1074\/jbc.M117.799593_bib9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cell.2013.11.049","article-title":"Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome","volume":"156","author":"Menon","year":"2014","journal-title":"Cell"},{"key":"10.1074\/jbc.M117.799593_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"10.1074\/jbc.M117.799593_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0898-6568(03)00040-8","article-title":"Tumour suppressors hamartin and tuberin: intracellular signalling","volume":"15","author":"Krymskaya","year":"2003","journal-title":"Cell. Signal"},{"key":"10.1074\/jbc.M117.799593_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1165\/rcmb.2005-0300OC","article-title":"Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: role for tumor suppressor TSC2","volume":"34","author":"Goncharova","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol"},{"key":"10.1074\/jbc.M117.799593_bib13","doi-asserted-by":"crossref","first-page":"30958","DOI":"10.1074\/jbc.M202678200","article-title":"Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)","volume":"277","author":"Goncharova","year":"2002","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M117.799593_bib14","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1083\/jcb.200405130","article-title":"TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase","volume":"167","author":"Goncharova","year":"2004","journal-title":"J. Cell Biol"},{"key":"10.1074\/jbc.M117.799593_bib15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1165\/rcmb.2005-0374OC","article-title":"Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis","volume":"34","author":"Goncharova","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol"},{"key":"10.1074\/jbc.M117.799593_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaip.2015.11.007","article-title":"Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis","volume":"4","author":"Sebaaly","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract"},{"key":"10.1074\/jbc.M117.799593_bib17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1586\/17476348.2015.1024663","article-title":"The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials","volume":"9","author":"El-Chemaly","year":"2015","journal-title":"Expert Rev. Respir. Med"},{"key":"10.1074\/jbc.M117.799593_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M117.799593_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1056\/NEJMc072500","article-title":"Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis","volume":"358","author":"Davies","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M117.799593_bib20","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1074\/jbc.M117.799593_bib21","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1074\/jbc.M117.799593_bib22","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M117.799593_bib23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1074\/jbc.M117.799593_bib24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: many loops in one pathway","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr. Opin. Cell Biol"},{"key":"10.1074\/jbc.M117.799593_bib25","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1172\/JCI58709","article-title":"Lymphangioleiomyomatosis\u2013a wolf in sheep's clothing","volume":"122","author":"Henske","year":"2012","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.M117.799593_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5500\/wjt.v6.i1.249","article-title":"Recurrence of lymphangioleiomyomatosis: nine years after a bilateral lung transplantation","volume":"6","author":"Zaki","year":"2016","journal-title":"World J. Transplant"},{"key":"10.1074\/jbc.M117.799593_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/hupa.2003.50","article-title":"Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis","volume":"34","author":"Bittmann","year":"2003","journal-title":"Hum. Pathol"},{"key":"10.1074\/jbc.M117.799593_bib28","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1164\/rccm.200208-969OC","article-title":"Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism","volume":"167","author":"Karbowniczek","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1074\/jbc.M117.799593_bib29","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201003-0489OC","article-title":"Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis","volume":"182","author":"Cai","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1074\/jbc.M117.799593_bib30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13058-014-0428-4","article-title":"uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies","volume":"16","author":"Duffy","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1074\/jbc.M117.799593_bib31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.7150\/thno.4953","article-title":"The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target","volume":"3","author":"O'Halloran","year":"2013","journal-title":"Theranostics"},{"key":"10.1074\/jbc.M117.799593_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9","article-title":"Urokinase plasminogen activator: a prognostic marker in multiple types of cancer","volume":"71","author":"Duffy","year":"1999","journal-title":"J. Surg. Oncol"},{"key":"10.1074\/jbc.M117.799593_bib33","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1021\/bi00540a035","article-title":"Positive regulation of activation of plasminogen by urokinase: differences in Km for (glutamic acid)-plasminogen and lysine-plasminogen and effect of certain \u03b1, \u03c9-amino acids","volume":"21","author":"Peltz","year":"1982","journal-title":"Biochemistry"},{"key":"10.1074\/jbc.M117.799593_bib34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0049-3848(83)90244-X","article-title":"A comparison of the abilities of plasma kallikrein, \u03b2-Factor XIIa, Factor XIa and urokinase to activate plasminogen","volume":"29","author":"Miles","year":"1983","journal-title":"Thromb. Res"},{"key":"10.1074\/jbc.M117.799593_bib35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1023\/A:1022300216202","article-title":"Binding of latent matrix metalloproteinase 9 to fibrin: activation via a plasmin-dependent pathway","volume":"22","author":"Makowski","year":"1998","journal-title":"Inflammation"},{"key":"10.1074\/jbc.M117.799593_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-5793(97)00175-0","article-title":"Involvement of PA\/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation","volume":"405","author":"Baramova","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1074\/jbc.M117.799593_bib37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1055\/s-0037-1616230","article-title":"Plasmin and matrix metalloproteinases in vascular remodeling","volume":"86","author":"Lijnen","year":"2001","journal-title":"Thromb. Haemost"},{"key":"10.1074\/jbc.M117.799593_bib38","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1091\/mbc.e09-07-0590","article-title":"Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action","volume":"21","author":"Ferrara","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"10.1074\/jbc.M117.799593_bib39","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1084\/jem.20030361","article-title":"Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D","volume":"198","author":"McColl","year":"2003","journal-title":"J. Exp. Med"},{"key":"10.1074\/jbc.M117.799593_bib40","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1083\/jcb.110.3.767","article-title":"Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity","volume":"110","author":"Saksela","year":"1990","journal-title":"J. Cell Biol"},{"key":"10.1074\/jbc.M117.799593_bib41","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1083\/jcb.132.6.1177","article-title":"Cooperative effect of TNF\u03b1, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity","volume":"132","author":"Koolwijk","year":"1996","journal-title":"J. Cell Biol"},{"key":"10.1074\/jbc.M117.799593_bib42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1164\/rccm.2010014","article-title":"Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis","volume":"166","author":"Inoue","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1074\/jbc.M117.799593_bib43","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1378\/chest.125.3.1063","article-title":"Transforming growth factor-\u03b21 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis","volume":"125","author":"Evans","year":"2004","journal-title":"Chest"},{"key":"10.1074\/jbc.M117.799593_bib44","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1172\/JCI117114","article-title":"The urokinase receptor is required for human monocyte chemotaxis in vitro","volume":"93","author":"Gyetko","year":"1994","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.M117.799593_bib45","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1096\/fasebj.12.11.1027","article-title":"FGF-2 stimulates migration of Kaposi's sarcoma-like vascular cells by HGF-dependent relocalization of the urokinase receptor","volume":"12","author":"Cavallaro","year":"1998","journal-title":"FASEB J"},{"key":"10.1074\/jbc.M117.799593_bib46","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/sj.onc.1210066","article-title":"Urokinase receptor primes cells to proliferate in response to epidermal growth factor","volume":"26","author":"Jo","year":"2007","journal-title":"Oncogene"},{"key":"10.1074\/jbc.M117.799593_bib47","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1160\/TH05-01-0021","article-title":"The urokinase receptor and the regulation of cell proliferation","volume":"93","author":"Mazzieri","year":"2005","journal-title":"Thromb. Haemost"},{"key":"10.1074\/jbc.M117.799593_bib48","doi-asserted-by":"crossref","first-page":"17449","DOI":"10.1074\/jbc.M413141200","article-title":"Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator","volume":"280","author":"Jo","year":"2005","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M117.799593_bib49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000469153","article-title":"Plasminogen activator inhibitors\u2013a review","volume":"40","author":"Kruithof","year":"1988","journal-title":"Enzyme"},{"key":"10.1074\/jbc.M117.799593_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1165\/rcmb.2004-0289OC","article-title":"Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor","volume":"32","author":"Zhe","year":"2005","journal-title":"Am. J. Respir. Cell Mol. Biol"},{"key":"10.1074\/jbc.M117.799593_bib51","doi-asserted-by":"crossref","first-page":"15029","DOI":"10.1074\/jbc.M115.678490","article-title":"Urokinase-type plasminogen activator (uPA) promotes angiogenesis by attenuating proline-rich homeodomain protein (PRH) transcription factor activity and de-repressing vascular endothelial growth factor (VEGF) receptor expression","volume":"291","author":"Stepanova","year":"2016","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M117.799593_bib52","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1091\/mbc.e12-04-0306","article-title":"Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer","volume":"24","author":"Asuthkar","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"10.1074\/jbc.M117.799593_bib53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1368-8375(97)00028-6","article-title":"Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis","volume":"34","author":"Nozaki","year":"1998","journal-title":"Oral Oncol"},{"key":"10.1074\/jbc.M117.799593_bib54","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1152\/ajpcell.00238.2015","article-title":"Tumor cell intravasation","volume":"311","author":"Chiang","year":"2016","journal-title":"Am. J. Physiol. Cell Physiol"},{"key":"10.1074\/jbc.M117.799593_bib55","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/jcp.46.5.479","article-title":"Comparison of the use of antibodies to \u03b1 smooth muscle actin and desmin in pulmonary lymphangioleiomyomatosis","volume":"46","author":"Matthews","year":"1993","journal-title":"J. Clin. Pathol"},{"key":"10.1074\/jbc.M117.799593_bib56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1165\/rcmb.2009-0050OC","article-title":"Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells","volume":"42","author":"Lee","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol"},{"key":"10.1074\/jbc.M117.799593_bib57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/lrb.2009.0013","article-title":"Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC)","volume":"8","author":"Kwiatkowski","year":"2010","journal-title":"Lymphat. Res. Biol"},{"key":"10.1074\/jbc.M117.799593_bib58","first-page":"1206","article-title":"Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice","volume":"59","author":"Kobayashi","year":"1999","journal-title":"Cancer Res"},{"key":"10.1074\/jbc.M117.799593_bib59","doi-asserted-by":"crossref","first-page":"154ra134","DOI":"10.1126\/scitranslmed.3003840","article-title":"Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)","volume":"4","author":"Goncharova","year":"2012","journal-title":"Sci. Transl. Med"},{"key":"10.1074\/jbc.M117.799593_bib60","doi-asserted-by":"crossref","first-page":"L694","DOI":"10.1152\/ajplung.00204.2003","article-title":"Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways","volume":"286","author":"Yu","year":"2004","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol"},{"key":"10.1074\/jbc.M117.799593_bib61","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1210\/endo.136.11.7588234","article-title":"Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo","volume":"136","author":"Howe","year":"1995","journal-title":"Endocrinology"},{"key":"10.1074\/jbc.M117.799593_bib62","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1210\/en.2007-1096","article-title":"Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1\/forkhead box O3a pathway","volume":"149","author":"Pew","year":"2008","journal-title":"Endocrinology"},{"key":"10.1074\/jbc.M117.799593_bib63","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/MCB.01061-10","article-title":"mTORC2 is required for proliferation and survival of TSC2-null cells","volume":"31","author":"Goncharova","year":"2011","journal-title":"Mol. Cell. Biol"},{"key":"10.1074\/jbc.M117.799593_bib64","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1073\/pnas.92.17.7686","article-title":"A synthetic inhibitor of the mitogen-activated protein kinase cascade","volume":"92","author":"Dudley","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.M117.799593_bib65","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1573399811666150804104858","article-title":"FoxO1 inhibitors: the future medicine for metabolic disorders?","volume":"12","author":"Pandey","year":"2016","journal-title":"Curr. Diabetes Rev"},{"key":"10.1074\/jbc.M117.799593_bib66","first-page":"183","article-title":"Energy depletion of bovine mammary epithelial cells activates AMPK and suppresses protein synthesis through inhibition of mTORC1 signaling","volume":"45","author":"Burgos","year":"2013","journal-title":"Horm. Metab. Res"},{"key":"10.1074\/jbc.M117.799593_bib67","doi-asserted-by":"crossref","first-page":"32081","DOI":"10.1074\/jbc.M502876200","article-title":"Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity","volume":"280","author":"Hahn-Windgassen","year":"2005","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M117.799593_bib68","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/MCB.21.3.952-965.2001","article-title":"Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a)","volume":"21","author":"Brunet","year":"2001","journal-title":"Mol. Cell. Biol"},{"key":"10.1074\/jbc.M117.799593_bib69","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/ijc.26156","article-title":"Anti-tumour\/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?","volume":"129","author":"Matthews","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1074\/jbc.M117.799593_bib70","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1055\/s-0033-1338127","article-title":"The apparent uPA\/PAI-1 paradox in cancer: more than meets the eye","volume":"39","author":"Kwaan","year":"2013","journal-title":"Semin. Thromb. Hemost"},{"key":"10.1074\/jbc.M117.799593_bib71","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI200317222","article-title":"Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR","volume":"112","author":"Zhang","year":"2003","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.M117.799593_bib72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0303-7207(02)00230-7","article-title":"Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells","volume":"196","author":"Hodges","year":"2002","journal-title":"Mol. Cell. Endocrinol"},{"key":"10.1074\/jbc.M117.799593_bib73","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am. J. Hum. Genet"},{"key":"10.1074\/jbc.M117.799593_bib74","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.ejhg.5201402","article-title":"Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype\u2013phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex","volume":"13","author":"Sancak","year":"2005","journal-title":"Eur. J. Hum. Genet"},{"key":"10.1074\/jbc.M117.799593_bib75","doi-asserted-by":"crossref","first-page":"40242","DOI":"10.1074\/jbc.M608116200","article-title":"Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin\/p70 S6K pathway","volume":"281","author":"Cao","year":"2006","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M117.799593_bib76","doi-asserted-by":"crossref","first-page":"e104809","DOI":"10.1371\/journal.pone.0104809","article-title":"Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1074\/jbc.M117.799593_bib77","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1165\/rcmb.2014-0033OC","article-title":"Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis","volume":"51","author":"Sun","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol"},{"key":"10.1074\/jbc.M117.799593_bib78","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.M117.799593_bib79","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol"},{"key":"10.1074\/jbc.M117.799593_bib80","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trecan.2016.03.008","article-title":"Emerging role of mTOR in the response to cancer therapeutics","volume":"2","author":"Ilagan","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1074\/jbc.M117.799593_bib81","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/BST0370217","article-title":"A complex interplay between Akt, TSC2 and the two mTOR complexes","volume":"37","author":"Huang","year":"2009","journal-title":"Biochem. Soc. Trans"},{"key":"10.1074\/jbc.M117.799593_bib82","doi-asserted-by":"crossref","first-page":"14056","DOI":"10.1073\/pnas.0706517104","article-title":"Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc","volume":"104","author":"Tremblay","year":"2007","journal-title":"Natl. Acad. Sci. U.S.A"},{"key":"10.1074\/jbc.M117.799593_bib83","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Sun","year":"2005","journal-title":"Cancer Res"},{"key":"10.1074\/jbc.M117.799593_bib84","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","article-title":"Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade","volume":"4","author":"Shi","year":"2005","journal-title":"Mol. Cancer Ther"},{"key":"10.1074\/jbc.M117.799593_bib85","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1074\/jbc.M117.799593_bib86","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1074\/jbc.M117.799593_bib87","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J. Clin. Invest"},{"key":"10.1074\/jbc.M117.799593_bib88","doi-asserted-by":"crossref","first-page":"30107","DOI":"10.1074\/jbc.M705325200","article-title":"The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor","volume":"282","author":"Greer","year":"2007","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M117.799593_bib89","doi-asserted-by":"crossref","first-page":"958","DOI":"10.18632\/oncotarget.381","article-title":"Mechanism of activation of AMPK and upregulation of OGG1 by rapamycin in cancer cells","volume":"2","author":"Habib","year":"2011","journal-title":"Oncotarget"},{"key":"10.1074\/jbc.M117.799593_bib90","doi-asserted-by":"crossref","first-page":"e88891","DOI":"10.1371\/journal.pone.0088891","article-title":"The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase","volume":"9","author":"Mori","year":"2014","journal-title":"PLoS One"},{"key":"10.1074\/jbc.M117.799593_bib91","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1164\/rccm.201607-1384ST","article-title":"Official American Thoracic Society\/Japanese Respiratory Society Clinical Practice Guidelines: lymphangioleiomyomatosis diagnosis and management","volume":"194","author":"McCormack","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1074\/jbc.M117.799593_bib92","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1164\/rccm.201405-0918OC","article-title":"Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis","volume":"190","author":"Yao","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1074\/jbc.M117.799593_bib93","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1593\/neo.91302","article-title":"Stromal cells and integrins: conforming to the needs of the tumor microenvironment","volume":"11","author":"Alphonso","year":"2009","journal-title":"Neoplasia"},{"key":"10.1074\/jbc.M117.799593_bib94","doi-asserted-by":"crossref","first-page":"L319","DOI":"10.1152\/ajplung.00395.2001","article-title":"Urokinase induces its own expression in Beas2B lung epithelial cells","volume":"283","author":"Shetty","year":"2002","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol"},{"key":"10.1074\/jbc.M117.799593_bib95","doi-asserted-by":"crossref","first-page":"42300","DOI":"10.18632\/oncotarget.15857","article-title":"Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K\/AKT and ERK signaling in esophageal squamous cell carcinoma","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"10.1074\/jbc.M117.799593_bib96","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0014-5793(87)80039-X","article-title":"Amiloride selectively inhibits the urokinase-type plasminogen activator","volume":"214","author":"Vassalli","year":"1987","journal-title":"FEBS Lett"},{"key":"10.1074\/jbc.M117.799593_bib97","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2174\/138161212799504885","article-title":"NHE-1: a promising target for novel anti-cancer therapeutics","volume":"18","author":"Loo","year":"2012","journal-title":"Curr. Pharm. Des"},{"key":"10.1074\/jbc.M117.799593_bib98","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0165-6147(94)90130-9","article-title":"Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?","volume":"15","author":"Fazioli","year":"1994","journal-title":"Trends Pharmacol. Sci"},{"key":"10.1074\/jbc.M117.799593_bib99","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0046-8177(06)80039-0","article-title":"Role of elastic fiber degradation in emphysema-like lesions of pulmonary lymphangiomyomatosis","volume":"21","author":"Fukuda","year":"1990","journal-title":"Hum. Pathol"},{"key":"10.1074\/jbc.M117.799593_bib100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1165\/rcmb.F267","article-title":"Lymphangioleiomyomatosis: a complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation","volume":"28","author":"Krymskaya","year":"2003","journal-title":"Am. J. Respir. Cell Mol. Biol"},{"key":"10.1074\/jbc.M117.799593_bib101","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0046-8177(97)90061-7","article-title":"Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM)","volume":"28","author":"Hayashi","year":"1997","journal-title":"Hum. Pathol"},{"key":"10.1074\/jbc.M117.799593_bib102","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.cellbio.17.1.463","article-title":"How matrix metalloproteinases regulate cell behavior","volume":"17","author":"Sternlicht","year":"2001","journal-title":"Annu. Rev. Cell Dev. Biol"},{"key":"10.1074\/jbc.M117.799593_bib103","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/0955-0674(95)80116-2","article-title":"Proteolytic remodeling of extracellular matrix","volume":"7","author":"Birkedal-Hansen","year":"1995","journal-title":"Curr. Opin. Cell Biol"},{"key":"10.1074\/jbc.M117.799593_bib104","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1749-6632.1994.tb24722.x","article-title":"Regulation of matrix metalloproteinase activity","volume":"732","author":"Murphy","year":"1994","journal-title":"Ann. N. Y. Acad. Sci"},{"key":"10.1074\/jbc.M117.799593_bib105","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1128\/MCB.00077-09","article-title":"FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases","volume":"29","author":"Storz","year":"2009","journal-title":"Mol. Cell. Biol"},{"key":"10.1074\/jbc.M117.799593_bib106","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1159\/000095248","article-title":"Urokinase induces matrix metalloproteinase-9\/gelatinase B expression in THP-1 monocytes via ERK1\/2 and cytosolic phospholipase A2 activation and eicosanoid production","volume":"43","author":"Menshikov","year":"2006","journal-title":"J. Vasc. Res"},{"key":"10.1074\/jbc.M117.799593_bib107","doi-asserted-by":"crossref","first-page":"17758","DOI":"10.1074\/jbc.M601812200","article-title":"Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels","volume":"281","author":"Alfano","year":"2006","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M117.799593_bib108","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1242\/jcs.114.18.3387","article-title":"Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK\/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells","volume":"114","author":"Ma","year":"2001","journal-title":"J. Cell Sci"},{"key":"10.1074\/jbc.M117.799593_bib109","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fphar.2015.00154","article-title":"Urokinase receptor and resistance to targeted anticancer agents","volume":"6","author":"Gonias","year":"2015","journal-title":"Front. Pharmacol"},{"key":"10.1074\/jbc.M117.799593_bib110","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0037-1615846","article-title":"Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system","volume":"82","author":"Blasi","year":"1999","journal-title":"Thromb. Haemost"},{"key":"10.1074\/jbc.M117.799593_bib111","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1023099415940","article-title":"The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy","volume":"22","author":"Sidenius","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"10.1074\/jbc.M117.799593_bib112","doi-asserted-by":"crossref","first-page":"152163","DOI":"10.1155\/2013\/152163","article-title":"LRP-1: a checkpoint for the extracellular matrix proteolysis","volume":"2013","author":"Etique","year":"2013","journal-title":"BioMed Res. Int"},{"key":"10.1074\/jbc.M117.799593_bib113","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1165\/rcmb.2010-0302OC","article-title":"Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice","volume":"45","author":"Nassar","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol"},{"key":"10.1074\/jbc.M117.799593_bib114","doi-asserted-by":"crossref","first-page":"29050","DOI":"10.1074\/jbc.M109.010249","article-title":"A novel signaling pathway: fibroblast nicotinic receptor \u03b11 binds urokinase and promotes renal fibrosis","volume":"284","author":"Zhang","year":"2009","journal-title":"J. Biol. Chem"},{"key":"10.1074\/jbc.M117.799593_bib115","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1160\/TH05-06-0457","article-title":"Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin \u03b1v\u03b23 induces signal transduction and enhances plasminogen activation","volume":"95","author":"Tarui","year":"2006","journal-title":"Thromb. Haemost"},{"key":"10.1074\/jbc.M117.799593_bib116","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.2741\/3488","article-title":"Structure, function and antagonists of urokinase-type plasminogen activator","volume":"14","author":"Vincenza Carriero","year":"2009","journal-title":"Front. Biosci"},{"key":"10.1074\/jbc.M117.799593_bib117","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/bjc.2013.62","article-title":"Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer","volume":"108","author":"Heinemann","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1074\/jbc.M117.799593_bib118","first-page":"1568","article-title":"Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines","volume":"146","author":"Howe","year":"1995","journal-title":"Am. J. Pathol"},{"key":"10.1074\/jbc.M117.799593_bib119","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212\u0394\u0394C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1074\/jbc.M117.799593_bib120","first-page":"109","article-title":"Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride","volume":"17","author":"Jankun","year":"1999","journal-title":"Cancer Biochem. Biophys"},{"key":"10.1074\/jbc.M117.799593_bib121","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/msb.2012.74","article-title":"Genome-wide analysis of FOXO3 mediated transcription regulation through RNA polymerase II profiling","volume":"9","author":"Eijkelenboom","year":"2013","journal-title":"Mol. Syst. Biol"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820327873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820327873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.M117.799593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T13:42:15Z","timestamp":1619876535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820327873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":121,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0021925820327873"],"URL":"https:\/\/doi.org\/10.1074\/jbc.m117.799593","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/jbc.M117.799593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}]}}